Trace Neuroscience Launches With $101 Million Series A Financing to Expand Genomic Medicine for Neurodegenerative Diseases
Lead program in amyotrophic lateral sclerosis (ALS) is an antisense oligonucleotide that restores UNC13A protein to preserve and potentially improve muscle function UNC13A is a genetically validated target with the potential to treat 97% of…